EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Artificial intelligence and machine learning‐assisted digital applications for biopharmaceutical manufacturing

Shyam Panjwani iD, Hao Wei, John Mason iD

Biotechnology Progress · 2026-03 · 42 (2)

DOI: 10.1002/btpr.70089 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biotechnology Progress, online erschienen am 10.11.2025. Verfasst von Shyam Panjwani und 2 weiteren Autor:innen. Beteiligte Einrichtung: CMC & Technology, Bayer Pharmaceuticals, Berkeley, California, USA. Hauptthemen laut MEDLINE: Machine Learning, Artificial Intelligence, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence and automation are no longer just buzzwords in the biopharmaceutical industry. The manufacturing of a class of biologics, comprising monoclonal antibodies, cell therapies, and gene therapies, is far more complex than that of traditional small molecule drugs. Therefore, applications based on artificial intelligence are essential for successfully manufacturing this new class of biologics more quickly and more economically. Some biologics manufacturers, academic researchers, and young entrepreneurs have already begun implementing artificial intelligence‐based applications to increase operational efficiency, enhance process understanding, improve process monitoring, and achieve better regulatory compliance. Regulatory guidance from health agencies on the use of artificial intelligence and machine learning is acting as a catalyst in the adoption process of these new technologies by the biopharmaceutical industry. Research in artificial intelligence and machine learning has also advanced significantly in the last decade. At the same time, new cloud technologies have made the development and deployment of machine learning applications much easier. Several examples of artificial intelligence and machine learning applications in monoclonal antibodies manufacturing already exist. Cell and gene therapy, which present the future of medicine, will also benefit from this new technology. Overall, advancements in this domain will essentially help better serve patients' needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Machine LearningArtificial IntelligenceBiological ProductsHumansAntibodies, MonoclonalDrug Industry

Stichwörter der Autor:innen

artificial intelligencebiopharmaceutical manufacturingcell and gene therapygenerative AImachine leaning

Substanzen

Biological ProductsAntibodies, Monoclonal

Autor:innen und Institutionen

  • CMC & Technology, Bayer Pharmaceuticals, Berkeley, California, USA.

ORCID-Profile: Shyam Panjwani, John Mason

Zitieren

APA

Panjwani, S., Wei, H., & Mason, J. (2026). Artificial intelligence and machine learning‐assisted digital applications for biopharmaceutical manufacturing. Biotechnology Progress, 42(2). https://doi.org/10.1002/btpr.70089

Vancouver

Panjwani S, Wei H, Mason J. Artificial intelligence and machine learning‐assisted digital applications for biopharmaceutical manufacturing. Biotechnology Progress. 2026;42(2). doi:10.1002/btpr.70089

BibTeX
@article{Panjwani2026,
  author = {Panjwani, Shyam and Wei, Hao and Mason, John},
  title = {Artificial intelligence and machine learning‐assisted digital applications for biopharmaceutical manufacturing},
  journal = {Biotechnology Progress},
  year = {2026},
  volume = {42},
  number = {2},
  doi = {10.1002/btpr.70089}
}
Kostenlos starten →